GPR55 and cancer: Investigations of GPR55-mediated cell death after treatment of different cancer cell lines with N-docosahexaenoyl dopamine (DHA-DA), considered as biased agonist of GPR55, showed increased expression and synthesis of nNOS as well as increased production of NO after DHA-DA stimulation.